Navigation Links
Triage® Drugs of Abuse Panels

ProductsTriage® Drugs of Abuse Panels
Company Biosite
Item Triage® Drugs of Abuse Panels
Features 
  • excellent discrimination around assay cutoffs
  • ensures accurate patient and proficiency results
  • superior specificity and minimized false negatives
  • template permits hard copy archive of results
  • tests for amphetamines, methamphetamines, barbituates, benzodiazepines, cannabinoids, cocaine, opiates, PCP, tricyclic antidepressants, methadone and propoxyphene
  • one positive and one negative control built-into device
  • no calibration, no moving parts
Description The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to nine commonly abused drugs in about 10 minutes.
Info Biosite
Customer Service:
Web site: http://www.biosite.com

Related medicine products :

1. Triage® C. difficile Panel
2. Triage® Cardiac Panel
3. Triage® TOX Drug Screen
4. Triage® Profiler Shortness of Breath Panel
5. Triage® Parasite Panel
6. Drugs of Abuse Urine Screen Control
7. Drugs of Abuse Array Cocaine Metabolite Assay
8. Drugs of Abuse Array Evidence Opiates Assay
9. Drugs of Abuse Array Evidence Methodone Assay
10. Drugs of Abuse Array Evidence Ampphetimine Assay
11. Drugs of Abuse Array Evidence Barbiturates Assay
Soft-Touch Timeter® 8 LPM Flowmeter With 1 Power take Off
Soft-Touch Timeter® 8 LPM Flowmeter
Oxygen Dial Flowmeters - Chemetron
... offers a complete line of flowmeters, available i...lable in a variety of calibrations to best suit yo...specific to the gas in use, the Amvex Flowmeter is... the U with I. For Power Take-Off add PT to the en...
Medicine Products:
(Date:11/25/2009)... New minimally-invasive pro...inus pain and decrease the risk of sinusitis, or s...e physicians of the Atlanta Snoring Institute. Te...and congested sinuses without having to remove any... The advantages of these breakthroughs in treating...
(Date:11/25/2009)...,, VANCOUVER,Nov.25/PRNewswire/-- AdamDreamHeal...ealingintentionschangesthephysiologyofsomeoneatadi...atatimeunknowntoavolunteerwhowasmonitoredbyaquanti...AandCanada. ,, OnNovember8inVancouver,B.C.Adami...ent.Tofocusintentions,Adamcreatedavideoclipofaspec...
(Date:11/24/2009)... Eating high amounts of salt is linked to a signi... disease, states a paper published today in the B...ied out jointly by the World Health Organization,s...University of Warwick and University Hospital in C...ion Excellence Centre in Hypertension based at the...
(Date:11/24/2009)...(Boston) Researchers from Boston University Schoo...medical Engineering Department have identified a n...distinguish between cancer and normal cells with a...earchers have developed a new computational strate...key biological pathways (molecular circuits) that ...
(Date:11/24/2009)...,, DALLAS,Nov.24/PRNewswire-USNewswire/--TheBay...rofoneofthelargestcancerclinicaltrialscooperativeg...heNationalCancerInstitute,SouthwestOncologyGroupco...s,andtoimprovethequalityoflifeforcancersurvivors. ...eradditional,importantclinicaltrialstocancerpatien...
Breaking Medicine News(10 mins):Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:High salt intake linked to strokes and cardiovascular disease 2Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2
... Nuvilex, Inc. (OTC Bulletin Board: NVLX.OB), form...mer products company with a portfolio of aesthetic...oducts, announced today that it intends to reduce ...lthy glucose metabolism, to raise customer awarene...
...nts have access to most comprehensive Spanish-lang.... , April 8 CVS Caremark (NYSE: CVS ) today an...k.com. The Web site makes it easier for Spanish-s...iption benefits. Plan participants can access the...
...Bowl MVP Eli Manning , who serves as the March of...d business and corporate leaders on Monday, April ...es. Devin Wenig, CEO, Thompson Reuters, and a memb...s Co-Anchor, Maurice DuBois , emceed the progra...
...althfinder.gov has long been recognized as a key r...fit health prevention information on the Internet....edible information catalogued on the site. But it ...nted. , Washington D.C. (...
...il 8 InfuSystem (OTC Bulletin Board: INHI; INHI...sion pumps and associated clinical services, today... on its Term Loan in addition to its normal quarte... million, to $24.1 million. The Term Loan was a r...
...arks on intentions for good nutrition but lack kno...April 8 It,s no surprise that with the current ec...at comes from their home(1) and healthy eating is ... researchers found that, in general, households a...
Other Medicine News:Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 2Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 3Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 4Health News:Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign 5Health News:CVS Caremark Launches Spanish Version of Caremark.com 2Health News:CVS Caremark Launches Spanish Version of Caremark.com 3Health News:Eli Manning and Top Corporate Leaders Rally to Help Save Babies 2Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--AnadysPharmaceutica...entatthe21stAnnualPiperJaffrayHealthcareConference....TheconferenceisbeingheldatTheNewYorkPalaceHotel.S...rofAnadys,willprovideanoverviewofAnadysanditsclini...orporatepresentationwillbesimultaneouslywebcastand...
(Date:11/24/2009)...ON,Calif.,Nov.24/PRNewswire-FirstCall/--ThoratecCo...dmechanicalcirculatorysupporttherapiestosave,suppo...ticipatinginthe21stAnnualPiperJaffrayHealthCareCon...cutivevicepresidentandchieffinancialofficer,willpr...ernStandardTime(5:30a.m.,PacificStandardTime). ,...
(Date:11/24/2009)...N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitute,a...epharmaceuticalandbiotechindustry,todayannouncedth...Thenew HospitalMarketplace e-courseisthenewestaddi...ries,acomprehensiveseriesofe-coursesdesignedtofill...owledgeforcommercialprofessionals. ,, Thenewthr...
Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 1 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 2 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 3 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 4 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 5 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 6 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 7 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 8 Contrave 28R 29 Obesity Research Phase 3 Program Meets Co Primary and Key Secondary Endpoints 3B Exceeds FDA Efficacy Benchmark for Obesity Treatment 52080 9Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 1Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 2Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 3Highlights of Economic and Business Growth in the Tampa Bay Region 28News Briefs 29 52073 4